- Hunter's Health Hacks
- Posts
- Your Lungs on GLPs
Happy Wednesday!
GLP-1s are all the rage right now.
Yes, they’re phenomenal for fat loss, appetite regulation, and metabolic reset.
But we are now entering a new era where the scientific literature is confirming what many of us in the optimization world have suspected.
These compounds are far more than weight-loss drugs.
A brand-new paper published this October in Nature’s Scientific Reports just revealed that GLP-1 receptor agonists might also protect and regenerate your lungs.
The study looked at more than 3 million real-world patients in the TriNetX U.S. Network.
It found that people using GLP-1 peptides had significantly lower rates of lung cancer, fibrosis, and respiratory infections compared with those using another common diabetes class, DPP-4 inhibitors.
In other words, the same molecule helping people get lean may also be quietly restoring the vitality of human lungs.
FYI, Until Friday November 14th at Midnight PST, BioLongevity Labs is offering 20% off seven fat-incinerating products. Use code HUNTERW to get an additional 15% off.
Discovery
The team working on the study used a new-user, active-comparator, retrospective cohort, essentially the gold standard for observational data.
They identified over 3.3 million adults with Type 2 diabetes from 2005 to 2020 and then created two matched groups:
201,000 new GLP-1 receptor-agonist users (exenatide, liraglutide, dulaglutide, semaglutide, etc.)
323,000 new DPP-4 inhibitor users (sitagliptin, linagliptin, saxagliptin, etc.)
After strict exclusions and 1-to-1 propensity-score matching on every relevant variable (age, sex, BMI, HbA1c, kidney function, lifestyle, and medication use), they ended up with 158,000 patients per group, perfectly balanced across demographics.
The follow-up stretched ten years, giving us nearly two decades of longitudinal lung data.
The primary focus was on lung cancer.
Additionally, the study examines outcomes such as influenza, pneumonia, acute lower-lung infections, suppurative lung disease, and pulmonary fibrosis.
This comprehensive approach helps us understand the various health issues related to lung conditions.
The Numbers
Here’s where it gets wild.
Across that 10-year window, GLP-1 users consistently outperformed their matched peers on every pulmonary metric measured.
Lung cancer:
1,083 cases vs 1,396 in controls. An 18 % reduction in risk.
Influenza & Pneumonia:
16,611 vs 19,444 cases. About a 6 % reduction in risk.
Other Lower-Lung Infections:
8,318 vs 10,396 cases. A 15 % reduction in risk.
Suppurative Lung Disease:
392 vs 586 cases. A 26 % reduction in risk.
Pulmonary Fibrosis:
1,792 vs 2,192 cases. An 8 % reduction in risk.
These results were consistent across every demographic.
Women, older adults over 65, those with obesity, and African American participants experienced the strongest benefits.
Even patients with reduced kidney function saw protective effects.
In short, GLP-1 therapy improves how you burn oxygen and how your body absorbs it.
But Why Though?
GLP-1 receptors are densely expressed in lung tissue.
When activated, they appear to regulate immune balance, suppress NF-κB signaling, reduce pro-inflammatory cytokines such as IL-6 and TNF-α, and restore mitochondrial redox status in alveolar cells.
Animal models show that GLP-1 agonists:
Down-regulate lung scarring
Restore ACE2 expression and rebalance the renin–angiotensin system
Increase surfactant-protein production, maintaining alveolar structure
Boost antioxidant enzymes such as SOD and catalase
Meanwhile, their metabolic benefits indirectly ease pulmonary strain.
Lower insulin levels mean less systemic inflammation, leading to improved vascular elasticity and micro-oxygenation.
Essentially, the same cellular pathways that heal metabolic dysfunction are the ones that prevent the lungs from literally rusting over time.
Good Candidates
If you experience any of the following, the pulmonary benefits of GLP-1s could be especially relevant:
A history of smoking or chronic environmental exposure (dust, pollution, second-hand smoke).
Post-viral lung irritation (long-COVID or recurrent bronchitis).
Asthma or mild COPD with systemic inflammation.
Early fibrotic changes or scarring after infection.
Metabolic syndrome, insulin resistance, or obesity (all of which compromise lung elasticity).
These peptides appear to strengthen the respiratory system from the inside out by reducing fibrosis, improving immune resilience, and dampening the chronic inflammatory cascade that drives pulmonary aging.
For biohackers and longevity seekers, this hints that GLP-1s might not just extend lifespan, but health-span of breath itself.
Imagine a molecule that lets you breathe like your younger self while helping you stay lean.
That’s where things are headed.
Final Thoughts
I personally watched my father-in-law recover from COPD in record time using peptides, including retatrutide.
I’ve witnessed the lung health benefits firsthand.
And every time a study like this drops, it widens the aperture on what we mean by “metabolic therapy.”
GLP-1 agonists started as diabetes drugs, became fat-loss tools, and are now revealing themselves as multi-system regenerative agents.
They improve cardiovascular outcomes, kidney function, inflammation, cognition, and now, lung integrity.
If these data hold up in randomized prospective trials, we’re looking at a new class of longevity medicine that protects both our metabolic and respiratory engines.
In the future, it’s possible we could see lower lung cancer rates, fewer respiratory infections, less chronic fibrosis, better oxygen utilization, and ultimately higher energy and cognition.
From a planetary-health perspective, this could add billions of cumulative “breath-years” back to humanity.
And that’s a vision of the future worth fighting for.
Best,
Hunter Williams
Further Reading